Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Status Not yet recruiting

Clinical Trial Summary

This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.

Clinical Trial Description

This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in metastatic TNBC (triple negative breast cancer) patients who progressed during or following previous chemotherapy. Chemotherapy is the backbone drug for TNBC. How to reverse chemotherapy resistance or how to increase the sensitivity of chemotherapy efficacy, has become an urgent clinical problem to be solved. The preclinical results show that Inosine play a potentially important role in regulating the tumor microenvironment. The investigators found that inosine from intestinal probiotics was negatively correlated with breast cancer recurrence and metastasis after chemotherapy, and further functional experiments showed that inosine-producing flora or dietary supplementation with inosine could significantly inhibit the survival of tumor cells after chemotherapy and inhibit the recurrence and metastasis of breast cancer. Furthermore, it is considered to have a high level of safety. Based on preclinical studies, the investigators designed this study to enroll mTNBC patients who have progressed during or following chemotherapy, and to explore the efficacy of combined inosine with chemotherapy at a clinical level, providing new strategies of combined treatment for TNBC patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06355024
Study type	Interventional
Source	Fudan University
Contact	Zhimin Shao, MD, PhD
Phone	08664175590
Email	zhimingshao@yahoo.com
Status	Not yet recruiting
Phase	Phase 2
Start date	April 10, 2024
Completion date	January 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03639948` - Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer	Phase 2
Withdrawn	`NCT02427581` - Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy	Phase 1
Completed	`NCT04584112` - A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer	Phase 1
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Terminated	`NCT01918306` - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT04914390` - A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer	Phase 2
Completed	`NCT03154749` - DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer	Phase 2
Completed	`NCT04504916` - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)	Phase 2
Completed	`NCT03345485` - Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04582955` - Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy	N/A
Terminated	`NCT04099277` - A Study of LY3435151 in Participants With Solid Tumors	Phase 1
Withdrawn	`NCT01695057` - Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer	N/A
Terminated	`NCT01234532` - Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery	Phase 2
Recruiting	`NCT03805399` - FUSCC Refractory TNBC Umbrella (FUTURE)	Phase 1/Phase 2
Active, not recruiting	`NCT04129996` - A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)	Phase 2
Terminated	`NCT03621982` - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors	Phase 1
Recruiting	`NCT05336721` - A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC	Phase 2
Terminated	`NCT03674827` - Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC	Phase 1
Completed	`NCT04177108` - A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer	Phase 3